The Index 2010
The Index 2010 report covers 27 pharmaceutical companies, comprising 20 originators and seven generics manufacturers. The ranking is based on 106 indicators that measure activities across four strategic and seven technical areas. The research and analysis for the Index 2010 was conducted by MSCI/Risk Metrics.
Click through the chart to view how originator companies ranked in the Access to Medicine Index 2010. Download the Access to Medicine Index 2010 Report or visit our Index Report Site where you can create your own Index Report. Scroll down even further to view the generics industry ranking.
Results per criterium
-
All criteria
1 GlaxoSmithKline PLC 3.7 2 Merck & Co. Inc. 3.1 3 Novartis AG 2.9 4 Gilead Sciences 2.5 5 Sanofi-Aventis 2.3 6 Roche Holdings Ltd. 2.3 7 AstraZeneca PLC 2.2 8 Novo Nordisk A/S 2.1 9 Johnson & Johnson 2.1 10 Abbott Laboratories Inc. 2.1 11 Pfizer Inc. 2.1 12 Boehringer-Ingelheim 1.9 13 Eli Lilly & Co. 1.8 14 Bayer AG 1.8 15 Bristol-Myers Squibb Co. 1.6 16 Eisai Co. Ltd. 1.3 17 Merck KGaA 1.2 18 Takeda Pharmaceutical Co. 0.8 19 Astellas Pharma Inc. 0.6 20 Daiichi Sankyo Co. Ltd. 0.6 -
Management
1 GlaxoSmithKline PLC 4.4 2 Merck & Co. Inc. 4.2 3 Gilead Sciences 3.8 4 Sanofi-Aventis 3.6 5 Novartis AG 3.6 6 Novo Nordisk A/S 3.5 7 AstraZeneca PLC 3.5 8 Roche Holdings Ltd. 3.5 9 Abbott Laboratories Inc. 3.1 10 Bayer AG 3.0 11 Pfizer Inc. 2.9 12 Eli Lilly & Co. 2.7 13 Johnson & Johnson 2.7 14 Bristol-Myers Squibb Co. 2.2 15 Boehringer-Ingelheim 2.2 16 Merck KGaA 1.5 17 Takeda Pharmaceutical Co. 1.1 18 Daiichi Sankyo Co. Ltd. 0.3 19 Eisai Co. Ltd. 0.2 20 Astellas Pharma Inc. 0.1 -
Influence
1 GlaxoSmithKline PLC 3.3 2 Abbott Laboratories Inc. 2.7 3 Novartis AG 2.7 4 AstraZeneca PLC 2.7 5 Merck & Co. Inc. 2.6 6 Pfizer Inc. 2.6 7 Sanofi-Aventis 2.5 8 Merck KGaA 2.4 9 Bayer AG 2.4 10 Roche Holdings Ltd. 2.4 11 Bristol-Myers Squibb Co. 2.4 12 Johnson & Johnson 2.3 13 Eli Lilly & Co. 2.3 14 Novo Nordisk A/S 2.2 15 Gilead Sciences 2.1 16 Eisai Co. Ltd. 1.8 17 Astellas Pharma Inc. 1.8 18 Takeda Pharmaceutical Co. 1.7 19 Boehringer-Ingelheim 1.7 20 Daiichi Sankyo Co. Ltd. 1.3 -
R&D
1 GlaxoSmithKline PLC 4.0 2 Novartis AG 3.3 3 Sanofi-Aventis 2.8 4 Merck & Co. Inc. 2.5 5 Pfizer Inc. 2.2 6 Eisai Co. Ltd. 1.8 7 Johnson & Johnson 1.8 8 AstraZeneca PLC 1.8 9 Roche Holdings Ltd. 1.8 10 Gilead Sciences 1.5 11 Bayer AG 1.5 12 Merck KGaA 1.4 13 Novo Nordisk A/S 1.4 14 Abbott Laboratories Inc. 1.3 15 Eli Lilly & Co. 1.2 16 Bristol-Myers Squibb Co. 0.8 17 Boehringer-Ingelheim 0.7 18 Daiichi Sankyo Co. Ltd. 0.7 19 Takeda Pharmaceutical Co. 0.5 20 Astellas Pharma Inc. 0.3 -
Pricing
1 GlaxoSmithKline PLC 3.4 2 Gilead Sciences 3.4 3 Merck & Co. Inc. 3.3 4 Novo Nordisk A/S 3.0 5 Abbott Laboratories Inc. 2.7 6 Novartis AG 2.5 7 Sanofi-Aventis 1.9 8 Johnson & Johnson 1.8 9 Roche Holdings Ltd. 1.8 10 Boehringer-Ingelheim 1.6 11 Bayer AG 1.5 12 AstraZeneca PLC 1.3 13 Pfizer Inc. 1.2 14 Bristol-Myers Squibb Co. 1.2 15 Eli Lilly & Co. 1.2 16 Eisai Co. Ltd. 1.0 17 Daiichi Sankyo Co. Ltd. 0.8 18 Takeda Pharmaceutical Co. 0.6 19 Astellas Pharma Inc. 0.5 20 Merck KGaA 0.3 -
Patenting
1 GlaxoSmithKline PLC 3.4 2 Boehringer-Ingelheim 3.2 3 Merck & Co. Inc. 3.0 4 Gilead Sciences 2.7 5 Eli Lilly & Co. 2.3 6 Bristol-Myers Squibb Co. 2.2 7 Roche Holdings Ltd. 2.1 8 AstraZeneca PLC 1.8 9 Novartis AG 1.8 10 Novo Nordisk A/S 1.8 11 Johnson & Johnson 1.7 12 Astellas Pharma Inc. 1.6 13 Eisai Co. Ltd. 1.6 14 Sanofi-Aventis 1.4 15 Pfizer Inc. 1.4 16 Bayer AG 1.1 17 Abbott Laboratories Inc. 0.8 18 Merck KGaA 0.8 19 Takeda Pharmaceutical Co. 0.6 20 Daiichi Sankyo Co. Ltd. 0.6 -
Capability
1 GlaxoSmithKline PLC 3.6 2 Novartis AG 3.4 3 Merck & Co. Inc. 2.4 4 Roche Holdings Ltd. 2.2 5 AstraZeneca PLC 2.2 6 Eli Lilly & Co. 1.9 7 Gilead Sciences 1.9 8 Johnson & Johnson 1.7 9 Boehringer-Ingelheim 1.6 10 Pfizer Inc. 1.5 11 Abbott Laboratories Inc. 1.5 12 Eisai Co. Ltd. 1.5 13 Sanofi-Aventis 1.2 14 Bayer AG 1.1 15 Merck KGaA 1.1 16 Novo Nordisk A/S 1.0 17 Takeda Pharmaceutical Co. 0.8 18 Bristol-Myers Squibb Co. 0.8 19 Daiichi Sankyo Co. Ltd. 0.3 20 Astellas Pharma Inc. 0.0 -
Philanthropy
1 Merck & Co. Inc. 4.4 2 GlaxoSmithKline PLC 4.3 3 Pfizer Inc. 3.7 4 Roche Holdings Ltd. 3.5 5 AstraZeneca PLC 3.5 6 Johnson & Johnson 3.4 7 Boehringer-Ingelheim 3.3 8 Novartis AG 3.2 9 Sanofi-Aventis 3.0 10 Bristol-Myers Squibb Co. 3.0 11 Abbott Laboratories Inc. 3.0 12 Eli Lilly & Co. 2.7 13 Bayer AG 2.6 14 Novo Nordisk A/S 2.4 15 Gilead Sciences 2.2 16 Merck KGaA 1.8 17 Takeda Pharmaceutical Co. 1.6 18 Astellas Pharma Inc. 0.3 19 Eisai Co. Ltd. 0.2 20 Daiichi Sankyo Co. Ltd. 0.1
Results per company
-
GlaxoSmithKline PLC
3.7- Management
-
4.4
- Influence
-
3.3
- R&D
-
4.0
- Pricing
-
3.4
- Patenting
-
3.4
- Capability
-
3.6
- Philanthropy
-
4.3
-
Merck & Co. Inc.
3.1- Management
-
4.2
- Influence
-
2.6
- R&D
-
2.5
- Pricing
-
3.3
- Patenting
-
3.0
- Capability
-
2.4
- Philanthropy
-
4.4
-
Novartis AG
2.9- Management
-
3.6
- Influence
-
2.7
- R&D
-
3.3
- Pricing
-
2.5
- Patenting
-
1.8
- Capability
-
3.4
- Philanthropy
-
3.2
-
Gilead Sciences
2.5- Management
-
3.8
- Influence
-
2.1
- R&D
-
1.5
- Pricing
-
3.4
- Patenting
-
2.7
- Capability
-
1.9
- Philanthropy
-
2.2
-
Sanofi-Aventis
2.3- Management
-
3.6
- Influence
-
2.5
- R&D
-
2.8
- Pricing
-
1.9
- Patenting
-
1.4
- Capability
-
1.2
- Philanthropy
-
3.0
-
Roche Holdings Ltd.
2.3- Management
-
3.5
- Influence
-
2.4
- R&D
-
1.8
- Pricing
-
1.8
- Patenting
-
2.1
- Capability
-
2.2
- Philanthropy
-
3.5
-
AstraZeneca PLC
2.2- Management
-
3.5
- Influence
-
2.7
- R&D
-
1.8
- Pricing
-
1.3
- Patenting
-
1.8
- Capability
-
2.2
- Philanthropy
-
3.5
-
Novo Nordisk A/S
2.1- Management
-
3.5
- Influence
-
2.2
- R&D
-
1.4
- Pricing
-
3.0
- Patenting
-
1.8
- Capability
-
1.0
- Philanthropy
-
2.4
-
Johnson & Johnson
2.1- Management
-
2.7
- Influence
-
2.3
- R&D
-
1.8
- Pricing
-
1.8
- Patenting
-
1.7
- Capability
-
1.7
- Philanthropy
-
3.4
-
Abbott Laboratories Inc.
2.1- Management
-
3.1
- Influence
-
2.7
- R&D
-
1.3
- Pricing
-
2.7
- Patenting
-
0.8
- Capability
-
1.5
- Philanthropy
-
3.0
-
Pfizer Inc.
2.1- Management
-
2.9
- Influence
-
2.6
- R&D
-
2.2
- Pricing
-
1.2
- Patenting
-
1.4
- Capability
-
1.5
- Philanthropy
-
3.7
-
Boehringer-Ingelheim
1.9- Management
-
2.2
- Influence
-
1.7
- R&D
-
0.7
- Pricing
-
1.6
- Patenting
-
3.2
- Capability
-
1.6
- Philanthropy
-
3.3
-
Eli Lilly & Co.
1.8- Management
-
2.7
- Influence
-
2.3
- R&D
-
1.2
- Pricing
-
1.2
- Patenting
-
2.3
- Capability
-
1.9
- Philanthropy
-
2.7
-
Bayer AG
1.8- Management
-
3.0
- Influence
-
2.4
- R&D
-
1.5
- Pricing
-
1.5
- Patenting
-
1.1
- Capability
-
1.1
- Philanthropy
-
2.6
-
Bristol-Myers Squibb Co.
1.6- Management
-
2.2
- Influence
-
2.4
- R&D
-
0.8
- Pricing
-
1.2
- Patenting
-
2.2
- Capability
-
0.8
- Philanthropy
-
3.0
-
Eisai Co. Ltd.
1.3- Management
-
0.2
- Influence
-
1.8
- R&D
-
1.8
- Pricing
-
1.0
- Patenting
-
1.6
- Capability
-
1.5
- Philanthropy
-
0.2
-
Merck KGaA
1.2- Management
-
1.5
- Influence
-
2.4
- R&D
-
1.4
- Pricing
-
0.3
- Patenting
-
0.8
- Capability
-
1.1
- Philanthropy
-
1.8
-
Takeda Pharmaceutical Co.
0.8- Management
-
1.1
- Influence
-
1.7
- R&D
-
0.5
- Pricing
-
0.6
- Patenting
-
0.6
- Capability
-
0.8
- Philanthropy
-
1.6
-
Astellas Pharma Inc.
0.6- Management
-
0.1
- Influence
-
1.8
- R&D
-
0.3
- Pricing
-
0.5
- Patenting
-
1.6
- Capability
-
0.0
- Philanthropy
-
0.3
-
Daiichi Sankyo Co. Ltd.
0.6- Management
-
0.3
- Influence
-
1.3
- R&D
-
0.7
- Pricing
-
0.8
- Patenting
-
0.6
- Capability
-
0.3
- Philanthropy
-
0.1
The graph below illustrates the contribution of six generics manufacturers to access to medicine. For more detailed information and company profiles on the generics manufacturers click here.
* Apotex, which is not a publicly listed company, is not included in the ranking due to lack of sufficient and reliable information about the company policies and operations.
Follow us
Access to Medicine Index
|
Scheepmakersdijk 5A
|
2011 AS
|
Haarlem
|
The Netherlands
|
Phone +31 23 533 91 87
|
info@atmindex.org
|
www.accesstomedicineindex.org